<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="70" ids="18291,35154">Manganese</z:chebi> <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase (MnSOD), <z:chebi fb="0" ids="16856">glutathione</z:chebi> peroxidase-1 (GPX1), and catalase (CAT) provide the primary <z:chebi fb="11" ids="22586">antioxidant</z:chebi> defense system </plain></SENT>
<SENT sid="1" pm="."><plain>Impaired <z:chebi fb="11" ids="22586">antioxidant</z:chebi> defense increases <z:mp ids='MP_0003674'>oxidative stress</z:mp> and contributes to the development of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and diabetic <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>We preformed a case-control study in Chinese type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients, to determine if the MnSOD Val16Ala (T→C), GPX1 Pro198Leu (C→T), and CAT -262C/T (C→T) functional polymorphisms contribute to the development of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> or diabetic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (n = 168) were divided into the non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> group (n = 83, &gt;10 year since diagnosis) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> group (n = 85, history of ischemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>Genotyping was performed using PCR-restriction fragment length polymorphism (PCR-RFLP) or PCR-based direct sequencing </plain></SENT>
<SENT sid="5" pm="."><plain>The genotypic distribution in the non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>- and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>-group and the clinical parameters in genotypic groups were not significantly different in the three polymorphic sites, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Among eight genotypic combinations, the most common TT+CC+CC genotype (59.5%) was associated with higher <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels than the TT+CT+CC genotype, the second frequent one (14.9%; 1.77 ± 0.12 vs. 1.21 ± 0.11 mmol/l, P = 0.001), and <z:hpo ids='HP_0000001'>all</z:hpo> non-TT+CC+CC genotypes (40.5%; 1.77 ± 0.12 vs. 1.43 ± 0.12 mmol/l, P = 0.048) </plain></SENT>
<SENT sid="7" pm="."><plain>In the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> group, significantly <z:mp ids='MP_0005317'>elevated triglyceride levels</z:mp> were also observed in patients with TT+CC+CC compared to patients with TT+CT+CC (2.00 ± 0.18 vs. 1.37 ± 0.16 mmol/l, P = 0.018) or non-TT+CC+CC genotypes (2.00 ± 0.18 vs. 1.65 ± 0.19 mmol/l, P = 0.070) </plain></SENT>
<SENT sid="8" pm="."><plain>The common MnSOD, GPX1, and CAT TT+CC+CC genotype may contribute to <z:hpo ids='HP_0002155'>hypertriglyceridemia</z:hpo> in Chinese patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> or diabetic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
</text></document>